Royalty Pharma is the largest buyer of biopharmaceutical royalties, providing diversified non-operating exposure to top-selling drugs (Trelegy, Imbruvica, Tysabri, Evrysdi, etc.). The model captures upside from drug sales without R&D risk, with long-duration cash flows. Recent royalty acquisitions (cystic fibrosis, GLP-1 derivatives) extend portfolio durability. Internalization of management was a governance milestone. Yield + growth at GLP-1-aware valuations is attractive.
Thesis reviewed May 29, 2026
Royalty Pharma plc is headquartered in United States, which is currently showing elevated risk signals.
🇺🇸United States82EXITView United States risk detail →💊Pharma0NEUTRAL| Ticker | Company | Score | Gap | Signal Δ | Action |
|---|---|---|---|---|---|
| AZN | AstraZeneca PLC | 50 | +11% | ↓0% | EARLY |
| JNJ | Johnson & Johnson | 50 | +8% | ↓0% | NEUTRAL |
| REGN | Regeneron Pharmaceuticals Inc. | 50 | -16% | ↓0% | AVOID |
| TAK | Takeda Pharmaceutical Company Limited | 50 | +10% | ↓0% | NEUTRAL |
| LLY | Eli Lilly and Company | 50 | +24% | ↓0% | EARLY |
| PFE | Pfizer Inc. | 50 | +6% | ↓0% | NEUTRAL |
| NVO | Novo Nordisk A/S | 50 | +15% | ↓0% | EARLY |
Investors who hold RPRX may also have indirect exposure through these country funds.
Royalty Pharma announces $1.5B royalty acquisition on cystic fibrosis franchise
Q1 royalty receipts grow 12% on Trelegy and Evrysdi strength
Estimates · Yahoo Finance · Not audited figures